Skip to main content
Top
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Insomnia | Review

Pediatric sleep disturbances and treatment with melatonin

Authors: Susanna Esposito, Daniela Laino, Renato D’Alonzo, Annalisa Mencarelli, Lorenza Di Genova, Antonella Fattorusso, Alberto Argentiero, Elisabetta Mencaroni

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Background

There are no guidelines concerning the best approach to improving sleep, but it has been shown that it can benefit the affected children and their entire families. The aim of this review is to analyse the efficacy and safety of melatonin in treating pediatric insomnia and sleep disturbances.

Main body

Sleep disturbances are highly prevalent in children and, without appropriate treatment, can become chronic and last for many years; however, distinguishing sleep disturbances from normal age-related changes can be a challenge for physicians and may delay treatment. Some published studies have shown that melatonin can be safe and effective not only in the case of primary sleep disorders, but also for sleep disorders associated with various neurological conditions. However, there is still uncertainty concerning dosing regimens and a lack of other data. The dose of melatonin should therefore be individualised on the basis of multiple factors, including the severity and type of sleep problem and the associated neurological pathology.

Conclusions

Melatonin can be safe and effective in treating both primary sleep disorders and the sleep disorders associated with various neurological conditions. However, there is a need for further studies aimed at identifying the sleep disordered infants and children who will benefit most from melatonin treatment, and determining appropriate doses based on the severity and type of disorder.
Literature
1.
go back to reference Sadeh A, Mindell JA, Owens J. Why care about sleep of infants and their parents? Sleep Med Rev. 2011;15:335–7.CrossRef Sadeh A, Mindell JA, Owens J. Why care about sleep of infants and their parents? Sleep Med Rev. 2011;15:335–7.CrossRef
2.
go back to reference Mindell JA. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006;117:1223–32.CrossRef Mindell JA. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006;117:1223–32.CrossRef
3.
go back to reference Beebe DW. Neurobehavioral morbidity associated with disordered breathing during sleep in children: a comprehensive review. Sleep. 2006;29:1115–34.CrossRef Beebe DW. Neurobehavioral morbidity associated with disordered breathing during sleep in children: a comprehensive review. Sleep. 2006;29:1115–34.CrossRef
4.
go back to reference Meltzer LJ, Johnson C, Crosette J, Ramos M, Mindell JA. Prevalence of diagnosed sleep disorders in pediatric primary care practices. Pediatrics. 2010;125:e1410–8.CrossRef Meltzer LJ, Johnson C, Crosette J, Ramos M, Mindell JA. Prevalence of diagnosed sleep disorders in pediatric primary care practices. Pediatrics. 2010;125:e1410–8.CrossRef
5.
go back to reference Honaker SM, Meltzer LJ. Bedtime problems and night wakings in young children: an update of the evidence. Paediatr Respir Rev. 2014;15:333–9. Honaker SM, Meltzer LJ. Bedtime problems and night wakings in young children: an update of the evidence. Paediatr Respir Rev. 2014;15:333–9.
6.
go back to reference Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to adolescence: reference values and generational trends. Pediatrics. 2003;111:302–7.CrossRef Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to adolescence: reference values and generational trends. Pediatrics. 2003;111:302–7.CrossRef
7.
go back to reference International Classification of Sleep Disorders. Third ed. 2014: American Academy of Sleep Medicine. International Classification of Sleep Disorders. Third ed. 2014: American Academy of Sleep Medicine.
8.
go back to reference Owens JA, Mindell JA. Pediatric insomnia. Pediatr Clin North Am. 2011;58:555–69.CrossRef Owens JA, Mindell JA. Pediatric insomnia. Pediatr Clin North Am. 2011;58:555–69.CrossRef
9.
go back to reference Jan JE. Neurophysiology of circadian rhythm sleep disorders of children with neurodevelopmental disabilities. Eur J Paediatr Neurol. 2012;16:403–12.CrossRef Jan JE. Neurophysiology of circadian rhythm sleep disorders of children with neurodevelopmental disabilities. Eur J Paediatr Neurol. 2012;16:403–12.CrossRef
10.
go back to reference Reynolds AM, Malow BA. Sleep and autism spectrum disorders. Pediatr Clin North Am. 2011;58:685–98.CrossRef Reynolds AM, Malow BA. Sleep and autism spectrum disorders. Pediatr Clin North Am. 2011;58:685–98.CrossRef
11.
go back to reference Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, & possible biopsychosocial aetiologies. Sleep Med Rev. 2009;13:403–11.CrossRef Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, & possible biopsychosocial aetiologies. Sleep Med Rev. 2009;13:403–11.CrossRef
12.
go back to reference Krakowiak P. Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-based study. J Sleep Res. 2008;17:197–206.CrossRef Krakowiak P. Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: a population-based study. J Sleep Res. 2008;17:197–206.CrossRef
13.
go back to reference Chang Y, Chiang B. Mechanism of sleep disturbance in children with atopic dermatitis and the role of the circadian rhythm and melatonin. Int J Mol Sci. 2016;17:462–72.CrossRef Chang Y, Chiang B. Mechanism of sleep disturbance in children with atopic dermatitis and the role of the circadian rhythm and melatonin. Int J Mol Sci. 2016;17:462–72.CrossRef
15.
go back to reference Stores G, Stores R. Sleep disorders and their clinical significance in children with Down syndrome. Dev Med Child Neurol. 2013;55:126–30.CrossRef Stores G, Stores R. Sleep disorders and their clinical significance in children with Down syndrome. Dev Med Child Neurol. 2013;55:126–30.CrossRef
16.
go back to reference Austeng ME, Øverland B, Kværner KJ, Andersson EM, Axelsson S, Abdelnoor M, Akre H. Obstructive sleep apnea in younger school children with Down syndrome. Int J Pediatr Otorhinolaryngol. 2014;78:1026–9.CrossRef Austeng ME, Øverland B, Kværner KJ, Andersson EM, Axelsson S, Abdelnoor M, Akre H. Obstructive sleep apnea in younger school children with Down syndrome. Int J Pediatr Otorhinolaryngol. 2014;78:1026–9.CrossRef
17.
go back to reference Beck Blackmer A. Feinstein JA: Management of sleep disorders in children with neurodevelopmental disorders: a review. Pharmacotherapy. 2016;36:84–98.CrossRef Beck Blackmer A. Feinstein JA: Management of sleep disorders in children with neurodevelopmental disorders: a review. Pharmacotherapy. 2016;36:84–98.CrossRef
18.
go back to reference Charuvastra A, Cloitre M. Safe enough to sleep: sleep disruptions associated with trauma, posttraumatic stress, and anxiety in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2009;18:877–91.CrossRef Charuvastra A, Cloitre M. Safe enough to sleep: sleep disruptions associated with trauma, posttraumatic stress, and anxiety in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2009;18:877–91.CrossRef
19.
go back to reference Lerner AB, Case JD, Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem. 1960;235:1992–7. Lerner AB, Case JD, Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem. 1960;235:1992–7.
20.
go back to reference Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab. 1991;73:1276–80.CrossRef Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab. 1991;73:1276–80.CrossRef
21.
go back to reference Burgess HJ, Molina TA. Home lighting before usual bedtime impacts circadian timing: a field study. Photochem Photobiol. 2014;90:723–6.CrossRef Burgess HJ, Molina TA. Home lighting before usual bedtime impacts circadian timing: a field study. Photochem Photobiol. 2014;90:723–6.CrossRef
22.
go back to reference Kennaway DJ. Melatonin and development: physiology and pharmacology. Semin Perinatol. 2000;24:258–66.CrossRef Kennaway DJ. Melatonin and development: physiology and pharmacology. Semin Perinatol. 2000;24:258–66.CrossRef
23.
go back to reference Sadeh A. Sleep and melatonin in infants: a preliminary study. Sleep. 1997;20:185–91. Sadeh A. Sleep and melatonin in infants: a preliminary study. Sleep. 1997;20:185–91.
24.
go back to reference LeBourgeois MK, Carskadon MA, Akacem LD. Circadian phase and its relationship to nighttime sleep in toddlers. J Biol Rhythms. 2013;28:322–31.CrossRef LeBourgeois MK, Carskadon MA, Akacem LD. Circadian phase and its relationship to nighttime sleep in toddlers. J Biol Rhythms. 2013;28:322–31.CrossRef
25.
go back to reference Attanasio A, Rager K, Gupta D. Ontogeny of circadian rhythmicity for melatonin, serotonin, and N-acetylserotonin in humans. J Pineal Res. 1986;3:251–6.CrossRef Attanasio A, Rager K, Gupta D. Ontogeny of circadian rhythmicity for melatonin, serotonin, and N-acetylserotonin in humans. J Pineal Res. 1986;3:251–6.CrossRef
26.
go back to reference Griefahn B, Brode P, Blaszkewicz M, Remer T. Melatonin production during childhood and adolescence: a longitudinal study on the excretion of urinary 6- hydroxymelatonin sulfate. J Pineal Res. 2003;34:26–31.CrossRef Griefahn B, Brode P, Blaszkewicz M, Remer T. Melatonin production during childhood and adolescence: a longitudinal study on the excretion of urinary 6- hydroxymelatonin sulfate. J Pineal Res. 2003;34:26–31.CrossRef
27.
go back to reference Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.CrossRef Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.CrossRef
28.
go back to reference Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH. Daily rhythm in human urinary melatonin. Science. 1975;187:169–71.CrossRef Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH. Daily rhythm in human urinary melatonin. Science. 1975;187:169–71.CrossRef
29.
go back to reference Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int. 1994;24:101–46.CrossRef Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int. 1994;24:101–46.CrossRef
30.
go back to reference Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61:383–410.CrossRef Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61:383–410.CrossRef
31.
go back to reference Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60:97–108.CrossRef Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60:97–108.CrossRef
32.
go back to reference Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry. 2009;48:894–908. Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry. 2009;48:894–908.
33.
go back to reference Cortese S, Lecendreux M, Mouren MC, Konofal E. ADHD and insomnia. J Am Acad Child Adolesc Psychiatry. 2006;45:384–5.CrossRef Cortese S, Lecendreux M, Mouren MC, Konofal E. ADHD and insomnia. J Am Acad Child Adolesc Psychiatry. 2006;45:384–5.CrossRef
34.
go back to reference Kirov R, Brand S. Sleep problems and their effect in ADHD. Expert Rev Neurother. 2014;14:287–99.CrossRef Kirov R, Brand S. Sleep problems and their effect in ADHD. Expert Rev Neurother. 2014;14:287–99.CrossRef
35.
go back to reference Cortese S, Brown TE, Corkum P. Assessment and management of sleep problems in youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2013;52:784–96.CrossRef Cortese S, Brown TE, Corkum P. Assessment and management of sleep problems in youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2013;52:784–96.CrossRef
36.
go back to reference Owens J, Gruber R, Brown T. Future research directions in sleep and ADHD: report of a consensus working group. J Atten Disord. 2013;17:550–64.CrossRef Owens J, Gruber R, Brown T. Future research directions in sleep and ADHD: report of a consensus working group. J Atten Disord. 2013;17:550–64.CrossRef
37.
go back to reference Cubero-Millán I, Molina-Carballo A, Machado-Casas I. Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes. Int J Mol Sci. 2014;15:17115–29.CrossRef Cubero-Millán I, Molina-Carballo A, Machado-Casas I. Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes. Int J Mol Sci. 2014;15:17115–29.CrossRef
38.
go back to reference Punja S, Nikles CJ, Senior H. Melatonin in youth: N-of-1 trials in a stimulant-treated ADHD population (MYNAP): study protocol for a randomized controlled trial. Trials. 2016;17:375–84.CrossRef Punja S, Nikles CJ, Senior H. Melatonin in youth: N-of-1 trials in a stimulant-treated ADHD population (MYNAP): study protocol for a randomized controlled trial. Trials. 2016;17:375–84.CrossRef
39.
go back to reference Sivertsen B, Posserud MB, Gillberg C. Sleep problems in children with autism spectrum problems: a longitudinal population-based study. Autism Int J Res Pract. 2012;16:139–50.CrossRef Sivertsen B, Posserud MB, Gillberg C. Sleep problems in children with autism spectrum problems: a longitudinal population-based study. Autism Int J Res Pract. 2012;16:139–50.CrossRef
40.
go back to reference Gagnon K, Godbout R. Melatonin and comorbidities in children with autism spectrum disorder. Curr Dev Disord Rep. 2018;5:197–206.CrossRef Gagnon K, Godbout R. Melatonin and comorbidities in children with autism spectrum disorder. Curr Dev Disord Rep. 2018;5:197–206.CrossRef
41.
go back to reference Goldman SE, Adkins KW, Calcutt MW. Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep. J Autism Dev Disord. 2014;44:2525–35.CrossRef Goldman SE, Adkins KW, Calcutt MW. Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep. J Autism Dev Disord. 2014;44:2525–35.CrossRef
42.
go back to reference McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Develop Med Child Neurol. 1998;40:186–92.CrossRef McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Develop Med Child Neurol. 1998;40:186–92.CrossRef
43.
go back to reference Hancock E, O’Callaghan F, Osborne J. Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. J Child Neurol. 2005;20:78–80.CrossRef Hancock E, O’Callaghan F, Osborne J. Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. J Child Neurol. 2005;20:78–80.CrossRef
44.
go back to reference O’Callaghan JF, Clarke AA, Hancoack E. Use of melatonin to treat sleep disorders in tuberous sclerosis. Develop Med Child Neurol. 1999;41:123–6.CrossRef O’Callaghan JF, Clarke AA, Hancoack E. Use of melatonin to treat sleep disorders in tuberous sclerosis. Develop Med Child Neurol. 1999;41:123–6.CrossRef
45.
go back to reference Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53:783–92.CrossRef Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53:783–92.CrossRef
46.
go back to reference Cortesi F, Giannotti F, Sebastiani T. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: aA randomized placebo-controlled trial. J Sleep Res. 2012;21:700–9.CrossRef Cortesi F, Giannotti F, Sebastiani T. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: aA randomized placebo-controlled trial. J Sleep Res. 2012;21:700–9.CrossRef
47.
go back to reference Cuomo BM, Vaz S, Lee EAL. Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis. Pharmacotherapy. 2017;37:555–78.CrossRef Cuomo BM, Vaz S, Lee EAL. Effectiveness of sleep-based interventions for children with autism spectrum disorder: a meta-synthesis. Pharmacotherapy. 2017;37:555–78.CrossRef
48.
go back to reference Harrington RA, Lee LC, Crum RM. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res off J Int Soc Autism Res. 2013;6:149–68.CrossRef Harrington RA, Lee LC, Crum RM. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res off J Int Soc Autism Res. 2013;6:149–68.CrossRef
49.
go back to reference Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Disabil Res. 2007;51:2–13.CrossRef Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Disabil Res. 2007;51:2–13.CrossRef
50.
go back to reference Frase L, Nissen C, Riemann D, Spiegelhalder K. Making sleep easier: pharmacological interventions for insomnia. Expert Opin Pharmacother. 2018;19:1465–73.CrossRef Frase L, Nissen C, Riemann D, Spiegelhalder K. Making sleep easier: pharmacological interventions for insomnia. Expert Opin Pharmacother. 2018;19:1465–73.CrossRef
51.
go back to reference Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103:1155–62.CrossRef Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103:1155–62.CrossRef
52.
go back to reference Braam W, Didden R, Smits M, Curfs L. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. J Intellect Dis Res. 2008;52:256–64.CrossRef Braam W, Didden R, Smits M, Curfs L. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. J Intellect Dis Res. 2008;52:256–64.CrossRef
53.
go back to reference Dodge N, Wilson AG. Melatonin for treatment of sleep disorders in children with developmental disabilities. J Child Neurol. 2001;16:581–4.CrossRef Dodge N, Wilson AG. Melatonin for treatment of sleep disorders in children with developmental disabilities. J Child Neurol. 2001;16:581–4.CrossRef
54.
go back to reference Wasdell M, Jan J, Bomben M. A randomized, placebo-controlled trail of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pin Res. 2007;4:57–64. Wasdell M, Jan J, Bomben M. A randomized, placebo-controlled trail of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pin Res. 2007;4:57–64.
55.
go back to reference De Leersnyder H, de Blois M, Vekemans M. Β1-andrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith–Magenis syndrome. J Med Genetics. 2001;38:586–90.CrossRef De Leersnyder H, de Blois M, Vekemans M. Β1-andrenergic antagonists improve sleep and behavioural disturbances in a circadian disorder, Smith–Magenis syndrome. J Med Genetics. 2001;38:586–90.CrossRef
56.
go back to reference Camfield P, Gordon K, Dooley J, Camfield C. Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: six “N of 1” trials. J Child Neurol. 1996;11:341–3.CrossRef Camfield P, Gordon K, Dooley J, Camfield C. Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: six “N of 1” trials. J Child Neurol. 1996;11:341–3.CrossRef
57.
go back to reference Sheldon H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet. 1998;351:1254.CrossRef Sheldon H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet. 1998;351:1254.CrossRef
58.
go back to reference Uberos J, Romero J, Molina-Carballo A, Muñoz-Hoyos A. Melatonin and elimination of kynurenines in children with Down’s syndrome. J Pediatr Endocrinol Metab. 2010;23:277–82.CrossRef Uberos J, Romero J, Molina-Carballo A, Muñoz-Hoyos A. Melatonin and elimination of kynurenines in children with Down’s syndrome. J Pediatr Endocrinol Metab. 2010;23:277–82.CrossRef
59.
go back to reference De Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr Neurol. 2011;45:23–6.CrossRef De Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr Neurol. 2011;45:23–6.CrossRef
60.
go back to reference Potocki L, Glaze D, Tan D. Circadian rhythm abnormalities of melatonin in Smith–Magenis syndrome. J Med Genetics. 2000;37:428–33.CrossRef Potocki L, Glaze D, Tan D. Circadian rhythm abnormalities of melatonin in Smith–Magenis syndrome. J Med Genetics. 2000;37:428–33.CrossRef
61.
go back to reference Zhdanova I, Wurtman R, Wagstaff J. Effects of low dose melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol Metab. 1999;12:57–67.CrossRef Zhdanova I, Wurtman R, Wagstaff J. Effects of low dose melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol Metab. 1999;12:57–67.CrossRef
62.
go back to reference Braam W, Didden R, Smits M, Curfs L. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial. J Child Neurol. 2008;23:649–54.CrossRef Braam W, Didden R, Smits M, Curfs L. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial. J Child Neurol. 2008;23:649–54.CrossRef
63.
go back to reference Annaz D, Hill CM, Ashworth A. Characterisation of sleep problems in children with Williams syndrome. Res Dev Disabil. 2011;32:164–9.CrossRef Annaz D, Hill CM, Ashworth A. Characterisation of sleep problems in children with Williams syndrome. Res Dev Disabil. 2011;32:164–9.CrossRef
64.
go back to reference Mason TB, Arens R, Sharman J. Sleep in children with Williams syndrome. Sleep Med. 2011;12:892–7.CrossRef Mason TB, Arens R, Sharman J. Sleep in children with Williams syndrome. Sleep Med. 2011;12:892–7.CrossRef
65.
go back to reference Woolfenden S, Sarkozy V, Ridley G. A systematic review of two outcomes in autism spectrum disorder e epilepsy and mortality. Dev Med Child Neurol. 2012;54:306–12.CrossRef Woolfenden S, Sarkozy V, Ridley G. A systematic review of two outcomes in autism spectrum disorder e epilepsy and mortality. Dev Med Child Neurol. 2012;54:306–12.CrossRef
66.
go back to reference Goldberg-Stern H, Oren H, Peled N, Garty BZ. Effect of melatonin on seizure frequency in intractable epilepsy: a pilot study. J Child Neurol. 2012;27:1524–8.CrossRef Goldberg-Stern H, Oren H, Peled N, Garty BZ. Effect of melatonin on seizure frequency in intractable epilepsy: a pilot study. J Child Neurol. 2012;27:1524–8.CrossRef
67.
go back to reference Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev. 2012;6:006967. Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev. 2012;6:006967.
68.
go back to reference Jain S, Besag FM. Does melatonin affect epileptic seizures? Int J Med Toxicol Drug Exp. 2013;36:207–15.CrossRef Jain S, Besag FM. Does melatonin affect epileptic seizures? Int J Med Toxicol Drug Exp. 2013;36:207–15.CrossRef
69.
go back to reference Bazil CW, Short D, Crispin D. Patients with intractable epilepsy have low melatonin, which increases following seizures. Neurology. 2000;55:1746–8.CrossRef Bazil CW, Short D, Crispin D. Patients with intractable epilepsy have low melatonin, which increases following seizures. Neurology. 2000;55:1746–8.CrossRef
70.
71.
go back to reference Jain SV, Horn PS, Simakajornboon N. Melatonin improves sleep in children with epilepsy: randomized, double-blind cross-over study. Sleep Med. 2015;16:637–44.CrossRef Jain SV, Horn PS, Simakajornboon N. Melatonin improves sleep in children with epilepsy: randomized, double-blind cross-over study. Sleep Med. 2015;16:637–44.CrossRef
72.
go back to reference Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, Hamilton D, Weiss MD. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57–64. Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, Hamilton D, Weiss MD. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57–64.
73.
go back to reference Nagtegaal JE, Smits M, Van Der Meer YG, Fischer-Steenvoorden MG. Melatonin: a survey of suspected adverse drug reactions. Sleep-Wake Res Netherl. 1996;7:115–8. Nagtegaal JE, Smits M, Van Der Meer YG, Fischer-Steenvoorden MG. Melatonin: a survey of suspected adverse drug reactions. Sleep-Wake Res Netherl. 1996;7:115–8.
74.
go back to reference Damiani JM, Sweet BV, Sohoni P. Melatonin: an option for managing sleep disorders in children with autism spectrum disorder. Am J Health-Syst Pharm. 2014;71:95–101.CrossRef Damiani JM, Sweet BV, Sohoni P. Melatonin: an option for managing sleep disorders in children with autism spectrum disorder. Am J Health-Syst Pharm. 2014;71:95–101.CrossRef
75.
go back to reference Ray CA. Melatonin attenuates the sympathetic nerve responses to orthostatic stress in humans. J Physiol. 2003;551:1043–8.CrossRef Ray CA. Melatonin attenuates the sympathetic nerve responses to orthostatic stress in humans. J Physiol. 2003;551:1043–8.CrossRef
76.
go back to reference Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018;28(10):699–710 (Epub Oct 11).CrossRef Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018;28(10):699–710 (Epub Oct 11).CrossRef
77.
go back to reference Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190–9 (Epub Oct 11).CrossRef Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190–9 (Epub Oct 11).CrossRef
Metadata
Title
Pediatric sleep disturbances and treatment with melatonin
Authors
Susanna Esposito
Daniela Laino
Renato D’Alonzo
Annalisa Mencarelli
Lorenza Di Genova
Antonella Fattorusso
Alberto Argentiero
Elisabetta Mencaroni
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1835-1

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.